nonmitogen
immunoglobulin
kappa
murin
monoclon
antibodi
mab
direct
alphabeta
heterodim
tlymphocyt
receptor
complex
hybridoma
first
produc
fuse
spleen
cell
balbc
mice
immun
human
peripher
blood
tlymphocyt
mutant
myeloma
cell
mab
produc
purifi
use
multistep
ion
exchang
molecular
siev
chromatographi
protocol
use
success
treat
acut
cellular
reject
renal
transplant
immunosuppress
induct
agent
heart
simultan
kidneypancrea
transplant
nonmitogen
caus
minim
cytokin
releas
treatment
reject
induct
immunosuppress
accomplish
significantli
fewer
milder
untoward
effect
cytokin
releas
syndrom
compar
sinc
direct
heterodim
epitop
spare
gamma
delta
region
gamma
delta
cell
uniqu
role
immun
respons
control
mani
seriou
human
diseas
perhap
facilit
develop
immunolog
toler
rel
short
durat
action
deplet
cell
day
unlik
protract
deplet
seen
thymoglobulin
blymphocyt
deplet
aforement
reagent
lack
prolong
lymphocyt
deplet
may
account
less
infect
observ
treatment
induct
immunosuppress
becom
standard
therapi
unit
state
transplant
program
use
agent
inhibit
first
reject
respons
drug
often
use
fall
three
categori
select
block
monoclon
antibodi
mab
basiliximab
daclizumab
polyclon
antisera
tlymphocyt
rabbit
antilymphocyt
globulin
thymoglobulin
mab
alemtuzumab
target
b
cell
latter
two
agent
signific
effect
bcell
initi
dose
mg
profoundli
suppress
tcell
day
bcell
day
thymoglobulin
significantli
suppress
tcell
day
profound
antibcel
effect
day
open
mani
window
opportunist
infect
figur
clearli
would
advantag
shorter
act
immunosuppress
agent
allow
tcell
recoveri
littl
effect
b
cell
therefor
produc
profound
longterm
immunosuppress
waid
dovepress
first
mab
shown
effect
treat
acut
cellular
reject
shortact
agent
howev
caus
signific
advers
event
includ
relat
mitogen
mark
stimul
inflammatori
cytokin
shortact
murin
immunoglobulin
kappa
mab
nonmitogen
vitro
develop
univers
kentucki
purpos
review
discuss
briefli
describ
manufactur
process
state
known
mechan
action
comparison
give
synopsi
clinic
efficaci
discuss
abil
therapi
spare
cell
may
import
infect
develop
toler
final
support
thesi
shorter
act
select
antitlymphocyt
monoclon
antibodi
may
better
choic
induct
immunosuppress
andor
treatment
acut
reject
nonmitogen
isotyp
murin
mab
produc
fuse
spleen
cell
balbc
mice
immun
human
peripher
blood
tlymphocyt
mutant
myeloma
cell
preliminari
screen
clone
three
time
limit
dilut
determin
direct
monomorph
antigen
express
postthym
peripher
blood
tcell
circul
cell
cell
precursor
help
colleg
pharmaci
univers
kentucki
initi
product
purif
lyophil
stabl
clinic
materi
achiev
approv
us
food
drug
administr
fda
tcell
deplet
although
first
lot
extract
mous
ascit
subsequ
lot
produc
vitro
purifi
proprietari
multistep
ion
exchang
molecular
siev
chromatographi
protocol
final
product
exhibit
protein
puriti
use
sdspage
analysi
pass
fda
recommend
test
bacteri
fungal
viral
steril
gener
safeti
pyrogen
propos
mechan
action
therapeut
effect
unmodifi
murin
antit
cell
mab
revers
acut
human
allograft
reject
depend
combin
antibodi
isotyp
idiotyp
interact
respect
ligand
epitop
success
specif
antigen
recognit
complex
mechan
action
murin
mab
includ
interact
fc
portion
high
affin
fc
gamma
receptor
present
monocyt
produc
immun
activ
follow
immunosuppress
murin
isotyp
specif
tcr
heterodim
region
complex
react
fc
gamma
receptor
thu
exhibit
reduc
immun
stimul
cytokin
releas
syndrom
tcr
specif
defin
abil
modul
tcr
wherea
modul
type
cell
receptor
sinc
direct
tcr
epsilon
part
complex
differ
idiotyp
isotyp
differ
well
murin
isotyp
therefor
human
antimous
antibodi
hama
direct
one
monoclon
antibodi
neutral
mab
crossreact
inde
patient
allograft
reject
respond
therapi
one
monoclon
antibodi
success
treat
altern
agent
attempt
fulli
human
unsuccess
date
howev
chimer
mab
appear
compar
parent
compound
vitro
jst
person
commun
figur
b
cell
respons
peak
incid
opportunist
infect
thymoglobulin
campath
administr
prevent
cellular
reject
dovepress
submit
manuscript
wwwdovepresscom
dovepress
induc
shortterm
lymphocyt
deplet
administr
result
rapid
declin
lymphoid
cell
count
respect
epitop
modul
recoveri
day
figur
mark
contrast
thymoglobulin
may
one
reason
infect
may
occur
mani
month
either
agent
administ
figur
establish
potent
cell
mitogen
vivo
vitro
wherea
studi
suggest
reduc
prolifer
peripher
blood
mononuclear
cell
pbmc
vitro
studi
perform
compar
abil
induc
prolifer
determin
whether
high
concentr
crosslink
plastic
remain
incap
induc
prolifer
respons
pbmc
five
normal
donor
test
day
cultur
solubl
dose
high
mcgml
nonmitogen
solubl
potent
mitogen
even
low
dose
order
compar
abil
induc
cytokin
secret
vitro
product
cytokin
pbmc
normal
donor
determin
ngml
strongli
stimul
tumor
necrosi
releas
wherea
ngml
fail
induc
detect
cytokin
releas
pbmc
sixday
test
period
dose
escal
studi
dose
ngml
fail
induc
releas
hour
exposur
vivo
plasma
sampl
kidney
transplant
patient
reject
allograft
undergo
monoclon
mab
antibodi
therapi
test
cytokin
level
sampl
collect
inform
consent
two
hour
follow
first
dose
either
underw
elisa
quantit
signific
six
patient
treat
exhibit
respons
likewis
group
exhibit
significantli
lower
respons
howev
statist
differ
observ
respons
figur
incub
pbmc
either
reveal
differ
vitro
express
transferrin
receptor
receptor
dr
activ
antigen
phytohemagglutinin
pha
induc
express
activ
antigen
test
none
pbmc
donor
test
exhibit
dr
antigen
express
follow
incub
molar
equival
mcgml
induc
express
induct
apoptosi
releas
cell
abil
induc
program
cell
death
apoptosi
well
document
accordingli
abil
induc
apoptosi
tcell
line
hour
incub
compar
use
dna
fragment
analysi
dexamethason
posit
control
induc
dna
fragment
definit
apoptosi
degre
apoptosi
quantit
use
flow
cytometr
method
media
control
exhibit
apoptot
posit
cell
increas
follow
incub
secret
cell
line
also
determin
follow
stimul
prove
weaker
stimulu
howev
abil
gener
cellular
signal
confirm
induct
apoptosi
releas
human
tcell
line
use
success
treat
acut
cellular
reject
renal
transplant
phase
clinic
trial
kidney
recipi
transplant
univers
kentucki
provid
treatment
biopsi
proven
acut
cellular
reject
equal
fewer
untoward
effect
less
cytokin
releas
cytokin
nephropathi
compar
serum
creatinin
began
fall
two
day
therapi
instead
three
day
peak
serum
creatinin
rise
seen
therapi
present
figur
consist
lack
mitogen
significantli
less
cytokin
releas
seen
administr
figur
addit
treat
patient
fewer
seriou
infect
ptld
signific
increas
develop
hama
success
use
immunosuppress
induct
agent
heart
transplant
simultan
kidneypancrea
transplant
also
use
tlymphocyt
deplet
harvest
bone
marrow
prior
haploident
bone
marrow
transplant
control
graft
versu
host
diseas
unlik
monoclon
polyclon
antibodi
prepar
experi
treat
acut
leukemia
aplast
anemia
specif
tcr
spare
tcell
specif
cell
heterodim
region
epitop
modul
tcr
wherea
bind
epsilon
portion
modul
entir
epitop
flow
cytometri
confirm
absenc
cell
induc
modul
howev
administr
tcell
persist
figur
spare
cell
also
confirm
multicent
bone
marrow
deplet
trial
sponsor
nation
heart
lung
blood
institut
sinc
onset
human
organ
transplant
mani
new
drug
ad
improv
transplant
outcom
addit
small
molecul
shorter
act
stapl
mainten
immunosuppress
includ
corticosteroid
calcineurin
inhibitor
purin
synthesi
mtor
prevent
cellular
reject
dovepress
submit
manuscript
wwwdovepresscom
dovepress
inhibitor
biolog
monoclon
polyclon
increasingli
use
induct
immunosuppress
treatment
reject
addit
drug
greatli
reduc
acut
reject
case
improv
longterm
graft
surviv
albeit
increas
incid
cytopenia
renal
insuffici
neurolog
complic
diabet
hyperlipidemia
infect
complic
ptld
novel
mab
short
durat
activ
allow
phenotyp
alter
lymphocyt
repopul
therapi
effect
b
lymphocyt
mitogen
therefor
produc
fewer
cytokin
induc
side
effect
appear
less
propens
toward
infecti
complic
one
uniqu
characterist
specif
lymphocyt
express
tcell
receptor
tcr
gener
lymphocyt
compos
tcell
peripher
blood
remaind
lymphocyt
express
tcr
mice
human
lymphocyt
primarili
locat
proxim
epitheli
tissu
includ
skin
bowel
lung
area
bodi
earli
contact
extern
environ
cell
play
major
role
host
firstlin
defens
bacteria
virus
fungi
import
function
differ
lymphocyt
popul
abil
lymphocyt
recogn
respond
stimuli
without
requir
antigen
process
present
accessori
cell
regard
contribut
innat
immun
ie
abil
react
quickli
without
requir
prior
antigen
process
anoth
import
featur
firstlin
defens
well
document
skin
skin
injur
mechan
popul
lymphocyt
call
dendrit
epiderm
cell
detc
respond
quickli
injuri
attach
keratinocyt
primari
cell
skin
detc
secret
pregrowth
factor
keratit
growth
factor
insulin
growth
factor
stimul
regrowth
epithelium
phenomenon
demonstr
murin
lung
presum
occur
injuri
occur
epitheli
tissu
exposur
mild
immun
respons
capac
allow
lymphocyt
control
varieti
infecti
agent
nocardia
asteroid
pneumocysti
carinii
mycobacterium
bovi
bordatella
pertussi
etc
tissu
cultur
cell
kill
tumor
cell
serum
creatinin
mgdl
dovepress
infect
virus
gammadelta
lymphocyt
also
abl
modul
inflammatori
respons
situ
ie
directli
recogn
molecul
induc
epitheli
cell
stress
respond
rapidli
also
control
host
immun
respons
therebi
present
limit
immunopatholog
may
occur
sustain
respons
initi
stress
taken
togeth
clear
lymphocyt
actual
critic
compon
immun
system
particular
refer
control
mani
opportunist
infect
mainten
homeostasi
current
drug
use
immunosuppress
induct
treatment
reject
suppress
lymphocyt
popul
exampl
thymoglobulin
suppress
lymphocyt
also
b
lymphocyt
suppress
b
lymphocyt
monocyt
two
monoclon
antibodi
uniqu
target
tcr
bma
two
differ
fact
bma
mitogen
henc
toxic
profil
quit
differ
studi
perform
demonstr
spare
lymphocyt
make
differ
solid
organ
transplant
outcom
increas
cell
day
postbon
marrow
transplant
predict
longterm
favor
outcom
howev
direct
evid
spare
lymphocyt
benefici
transplant
outcom
mostli
deriv
report
experi
use
cell
deplet
donor
marrowstem
cell
sever
center
solid
organ
transplant
trial
overal
infect
rate
compar
favor
induct
rabbit
antithymocyt
globulin
thymoglobulin
versu
basiliximab
simulect
rate
infect
month
reportedli
respect
studi
suggest
cell
appear
import
control
mani
seriou
human
diseas
unfortun
accompani
immunosuppress
cell
also
appear
capabl
facilit
develop
immunolog
toler
featur
could
maxim
use
transplant
immunosuppress
induct
treatment
reject
parenthet
may
particularli
use
composit
tissu
transplant
hypothesi
base
observ
siemionow
other
antirat
mab
direct
ab
chain
tcell
receptor
specif
bind
chain
spare
chain
tcell
receptor
prevent
cellular
reject
dovepress
submit
manuscript
wwwdovepresscom
dovepress
critic
import
develop
long
term
toler
allogen
composit
transplant
thu
spare
lymphocyt
may
provid
import
benefit
stem
cell
solid
organ
transplant
summari
murin
antihuman
cell
monoclon
antibodi
reduc
immun
activ
potenti
vitro
vivo
vitro
induc
dna
synthesi
express
activ
antigen
cytokin
releas
contrast
clinic
effect
revers
acut
renal
allograft
reject
exhibit
lower
morbid
induc
lower
level
infus
final
spare
lymphocyt
uniqu
import
role
immun
respons
ie
control
mani
seriou
human
diseas
induc
cell
immunosuppress
perhap
facilit
develop
immunolog
toler
given
appar
advantag
current
avail
polyclon
monoclon
reagent
would
shorter
act
immunosuppress
agent
better
therapeut
choic
time
paradigm
shift
author
report
conflict
interest
work
